Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Matching

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    172 result(s) found for: Matching. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2016-003016-12 Sponsor Protocol Number: TMC114FD2HTX1003 Start Date*: 2019-01-02
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A study to assess the acceptability/swallowability of DRV-containing FDC tablets in HIV-1 infected adolescents, using matching placebo tablets. Rezolsta: EMEA-001280-PIP01-12-M01 Decision: P/0...
    Medical condition: Human immunodeficiency virus (HIV) Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004313-15 Sponsor Protocol Number: NI-0401-01 Start Date*: 2006-07-14
    Sponsor Name:NovImmune S.A.
    Full Title: A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease
    Medical condition: Moderate to Severe Active Crohn´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000666-17 Sponsor Protocol Number: RR37_21_01 Start Date*: 2022-07-30
    Sponsor Name:Fidia Farmaceutici Spa
    Full Title: A Phase II double-blind, randomised, placebo-controlled study of efficacy and safety of Vibrio alginolyticus collagenase administered to patients with Dupuytren contracture
    Medical condition: Dupuytren contracture
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10013872 Dupuytren's contracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022472-31 Sponsor Protocol Number: Lidocaine1 Start Date*: 2010-12-23
    Sponsor Name:University Hospital of South Manchester
    Full Title: The effect of Lidocaine and its Delivery in Patients with Chronic Cough
    Medical condition: Chronic Cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000615-31 Sponsor Protocol Number: DIA-EC-Cupa1-01-22 Start Date*: 2022-05-26
    Sponsor Name:Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas
    Full Title: Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial in parallel groups which evaluates the clinical efficacy and safety of immunotherapy with the purified major aller...
    Medical condition: Allergic patients to the Cupressaceae pollen with moderate/severe allergic rhino conjunctivitis with or without controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002070-21 Sponsor Protocol Number: CRAD001C2240 Start Date*: 2006-10-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met...
    Medical condition: Renal cell carcinomas arise from the proximal tubal epithelium. Alternatively known as clear-cell cancer or renal adenocarcinoma, RCC is characterized by a distinct clear or granular cell appearanc...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003346-90 Sponsor Protocol Number: D0816C00014 Start Date*: 2017-04-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Res...
    Medical condition: Epithelian ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) PL (Completed) BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003794-98 Sponsor Protocol Number: MK-7902-007 Start Date*: 2019-02-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic nonsmall cell lung cancer (NSCLC) wh...
    Medical condition: Metastatic nonsmall cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005788-24 Sponsor Protocol Number: BA2005/21/02 Start Date*: 2007-02-15
    Sponsor Name:Bioalliance Pharma
    Full Title: A Randomised, Double-Blind, Single dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo...
    Medical condition: Herpes labialis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000550-31 Sponsor Protocol Number: 87,1,2007_01_30 Start Date*: 2007-10-01
    Sponsor Name:IFS gGmbH, Universitätsmedizin Göttingen
    Full Title: Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study
    Medical condition: relapse prevention of alcoholics suffering from persisting craving and/or affective symptoms
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005160-18 Sponsor Protocol Number: RP101-200 Start Date*: 2018-12-18
    Sponsor Name:Redwood Pharma AB
    Full Title: A Phase II, multicentre, randomised, placebo-controlled, double-masked trial of RP101 ophthalmic formulation versus vehicle in post-menopausal women with moderate to severe dry eye syndrome
    Medical condition: moderate or severe dry eye syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10013774 Dry eye PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001416-30 Sponsor Protocol Number: CP40617 Start Date*: 2018-12-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN...
    Medical condition: INFLUENZA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10016790 Flu LLT
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) SE (Completed) BE (Completed) DE (Completed) FR (Completed) FI (Completed) HU (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000872-25 Sponsor Protocol Number: 106372 Start Date*: 2008-08-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals’ adjuvanted influenza candidate vaccine [GSK2186877A], administered intramusc...
    Medical condition: Immunization against influenza in male and female subjects aged 65 years or older.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) EE (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000498-40 Sponsor Protocol Number: CRAD001N2301 Start Date*: 2009-06-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching pla...
    Medical condition: Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) AT (Completed) IT (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000791-38 Sponsor Protocol Number: WA42293 Start Date*: 2021-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Completed) DE (Completed) HU (Completed) GR (Prematurely Ended) FI (Completed) PT (Prematurely Ended) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000530-37 Sponsor Protocol Number: 24978 Start Date*: 2004-09-16
    Sponsor Name:Serono International S.A.
    Full Title: A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjec...
    Medical condition: Psoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickene...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000285-35 Sponsor Protocol Number: Cardoz-003 Start Date*: 2011-05-09
    Sponsor Name:Cardoz AB
    Full Title: An international, multi-centre, randomised, stratified, double-blinded, placebo-controlled, 4-parallel group trial investigating the efficacy and safety of three different dose levels of CRD007 a...
    Medical condition: Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through the abdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA is generally asymptom...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10000054 Abdominal aortic aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003341-32 Sponsor Protocol Number: MSC-GVHD1 Start Date*: 2008-06-26
    Sponsor Name:University medical Center Utrecht
    Full Title: Treatment of steroid resistant grade II to IV acute GVHD by infusion of mesenchymal stem cells expanded with human plasma and platelet lysate ; a phase I/II study
    Medical condition: MSCs may be useful for treating established severe GVHD after stem cell transplantation. Preliminary data on 40 patients with steroid refractory grade III-IV acute GvHD were recently presented (K L...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002876-15 Sponsor Protocol Number: MCMK0112 Start Date*: 2012-11-23
    Sponsor Name:Cassella-med GmbH & Co KG
    Full Title: A randomised, multi-centre, parallel group, double-blind, placebo- and active-controlled clinical study to assess the efficacy and safety of Octenidine lozenges in the treatment of acute sore throat.
    Medical condition: Acute pharyngitis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001384-68 Sponsor Protocol Number: TMC114FD2HTX1006 Start Date*: 2019-09-19
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Study to Assess the Acceptability of Scored Film-coated darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Tablets in HIV-1 Infected Pediatric Parti...
    Medical condition: Human Immunodeficiency Virus Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 17:58:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA